ERBB2 and breast cancer: The diagnosis of HER2-positive BC remains a vexing issue in clinical oncology.None of the existing diagnostic methods can fully settle the question andusually requires additional, costly, invasive, and sometimes complicated manipulations[26, 28].This problem becomes especially evident when determiningthe molecular characteristics of the identified tumor nodes (metastases) andchoosing the optimal level of systemic treatment.